Pneumococcal polysaccharide vaccine: a systematic review of clinical effectiveness in adults

L. Watson, B. J. Wilson, Norman Robert Waugh

Research output: Contribution to journalArticle

114 Citations (Scopus)

Abstract

Pneumococcal polysaccharide vaccine is recommended in western countries for individuals at high risk of pneumococcal illness. We undertook a systematic review of randomised controlled trials of pneumococcal vaccine in adults, to determine the effects on clinical outcomes. Results: In industrialised populations, no benefit was detected for outcomes other than pneumococcal bacteraemia, and thin, did not reach statistical significance. In non-industrial populations, clear benefit was demonstrated for mortality and all-cause pneumonia. Conclusion: Benefit from pneumococcal vaccination depends on the baseline risk of infection and characteristics of a given population. Evidence from randomised trials for widespread adult vaccination in industrial countries is lacking. (C) 2002 Elsevier Science Ltd. All rights reserved.

Original languageEnglish
Pages (from-to)2166-2173
Number of pages7
JournalVaccine
Volume20
Issue number17-18
DOIs
Publication statusPublished - 2002

Keywords

  • vaccination
  • pneumococcal
  • review
  • RANDOMIZED CONTROLLED TRIALS
  • OBSTRUCTIVE PULMONARY-DISEASE
  • PROTECTIVE EFFICACY
  • ELDERLY PEOPLE
  • PNEUMONIA
  • QUALITY
  • RECOMMENDATIONS
  • METAANALYSIS
  • PREVENTION
  • SEROTYPE

Cite this

Pneumococcal polysaccharide vaccine: a systematic review of clinical effectiveness in adults. / Watson, L.; Wilson, B. J.; Waugh, Norman Robert.

In: Vaccine, Vol. 20, No. 17-18, 2002, p. 2166-2173.

Research output: Contribution to journalArticle

Watson, L. ; Wilson, B. J. ; Waugh, Norman Robert. / Pneumococcal polysaccharide vaccine: a systematic review of clinical effectiveness in adults. In: Vaccine. 2002 ; Vol. 20, No. 17-18. pp. 2166-2173.
@article{08611d89ac264059875d02f3e1fbc7b5,
title = "Pneumococcal polysaccharide vaccine: a systematic review of clinical effectiveness in adults",
abstract = "Pneumococcal polysaccharide vaccine is recommended in western countries for individuals at high risk of pneumococcal illness. We undertook a systematic review of randomised controlled trials of pneumococcal vaccine in adults, to determine the effects on clinical outcomes. Results: In industrialised populations, no benefit was detected for outcomes other than pneumococcal bacteraemia, and thin, did not reach statistical significance. In non-industrial populations, clear benefit was demonstrated for mortality and all-cause pneumonia. Conclusion: Benefit from pneumococcal vaccination depends on the baseline risk of infection and characteristics of a given population. Evidence from randomised trials for widespread adult vaccination in industrial countries is lacking. (C) 2002 Elsevier Science Ltd. All rights reserved.",
keywords = "vaccination, pneumococcal, review, RANDOMIZED CONTROLLED TRIALS, OBSTRUCTIVE PULMONARY-DISEASE, PROTECTIVE EFFICACY, ELDERLY PEOPLE, PNEUMONIA, QUALITY, RECOMMENDATIONS, METAANALYSIS, PREVENTION, SEROTYPE",
author = "L. Watson and Wilson, {B. J.} and Waugh, {Norman Robert}",
year = "2002",
doi = "10.1016/S0264-410X(02)00112-3",
language = "English",
volume = "20",
pages = "2166--2173",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "17-18",

}

TY - JOUR

T1 - Pneumococcal polysaccharide vaccine: a systematic review of clinical effectiveness in adults

AU - Watson, L.

AU - Wilson, B. J.

AU - Waugh, Norman Robert

PY - 2002

Y1 - 2002

N2 - Pneumococcal polysaccharide vaccine is recommended in western countries for individuals at high risk of pneumococcal illness. We undertook a systematic review of randomised controlled trials of pneumococcal vaccine in adults, to determine the effects on clinical outcomes. Results: In industrialised populations, no benefit was detected for outcomes other than pneumococcal bacteraemia, and thin, did not reach statistical significance. In non-industrial populations, clear benefit was demonstrated for mortality and all-cause pneumonia. Conclusion: Benefit from pneumococcal vaccination depends on the baseline risk of infection and characteristics of a given population. Evidence from randomised trials for widespread adult vaccination in industrial countries is lacking. (C) 2002 Elsevier Science Ltd. All rights reserved.

AB - Pneumococcal polysaccharide vaccine is recommended in western countries for individuals at high risk of pneumococcal illness. We undertook a systematic review of randomised controlled trials of pneumococcal vaccine in adults, to determine the effects on clinical outcomes. Results: In industrialised populations, no benefit was detected for outcomes other than pneumococcal bacteraemia, and thin, did not reach statistical significance. In non-industrial populations, clear benefit was demonstrated for mortality and all-cause pneumonia. Conclusion: Benefit from pneumococcal vaccination depends on the baseline risk of infection and characteristics of a given population. Evidence from randomised trials for widespread adult vaccination in industrial countries is lacking. (C) 2002 Elsevier Science Ltd. All rights reserved.

KW - vaccination

KW - pneumococcal

KW - review

KW - RANDOMIZED CONTROLLED TRIALS

KW - OBSTRUCTIVE PULMONARY-DISEASE

KW - PROTECTIVE EFFICACY

KW - ELDERLY PEOPLE

KW - PNEUMONIA

KW - QUALITY

KW - RECOMMENDATIONS

KW - METAANALYSIS

KW - PREVENTION

KW - SEROTYPE

U2 - 10.1016/S0264-410X(02)00112-3

DO - 10.1016/S0264-410X(02)00112-3

M3 - Article

VL - 20

SP - 2166

EP - 2173

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 17-18

ER -